Exchange: NYSE·Updated 04:48 PM EDT
News
all
press releases
Medtronic announces cash dividend for second quarter of fiscal year 2027
Medtronic announces cash dividend for second quarter of fiscal year 2027 Medtronic announces cash dividend for second quarter of fiscal year 2027 PR Newswire GALWAY, Ireland, Aug. 20, 2026 GALWAY, Ireland, Aug. 20, 2026 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) onThursday...
PR Newswire
More News
Is IART Still Attractive as Its Low Valuation Meets Execution Risks?
Integra's steep valuation discount meets margin gains and cost savings, but modest growth, leverage and unresolved FDA risks keep execution in focus.
Zacks
Medtronic (MDT) Advances While Market Declines: Some Information for Investors
In the most recent trading session, Medtronic (MDT) closed at $92.09, indicating a +1.64% shift from the previous trading day.
Zacks
MDT vs. A: Which Stock Should Value Investors Buy Now?
MDT vs. A: Which Stock Is the Better Value Option?
Zacks
CNMD Jumps 16% in a Month as Investors Assess Whether It Can Last
CNMD's 16% monthly rally is backed by stronger growth, margin gains and raised earnings guidance, but cash-flow and execution risks remain.
Zacks
Is CNMD a Buy Now as Low Valuation Meets Persistent Execution Risk?
CNMD's low valuation and improved earnings outlook strengthen its appeal, but cash-flow pressure and execution risks keep the buy case measured.
Zacks
Can CONMED's Raised 2026 EPS Outlook Reinforce Its Growth Momentum?
CONMED raised its 2026 adjusted EPS outlook after a strong second quarter, but slower organic growth and higher financing costs keep the setup mixed.
Zacks
NeuroPace Faces an IGE Delay: What the FDA Setback Means for Growth
NPCE's IGE expansion faces a regulatory delay, shifting focus to rising RNS adoption as the company works through the FDA review process.
Zacks
Is NeuroPace a Buy as Growth Improves but Valuation Stays Elevated?
NPCE's stronger RNS adoption, narrowing losses and AI expansion support growth, but premium valuation, liquidity and regulatory risks warrant patience.
Zacks
NPCE Is Down 12.7% in 3 Months: Is the Pullback a Buying Opportunity?
NeuroPace's stronger RNS growth, raised 2026 guidance and AI expansion face a less certain IGE regulatory path after the FDA setback.
Zacks

Advertisement|Remove ads.